Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 22:2024:8034923.
doi: 10.1155/2024/8034923. eCollection 2024.

Clinical Burden of Chronic Obstructive Pulmonary Disease in Patients with Suboptimal Peak Inspiratory Flow

Jill A Ohar  1 , Donald A Mahler  2   3 , Gabrielle N Davis  4 , David A Lombardi  4 , Edmund J Moran  4 , Glenn D Crater  4
Affiliations

Clinical Burden of Chronic Obstructive Pulmonary Disease in Patients with Suboptimal Peak Inspiratory Flow

Jill A Ohar et al. Can Respir J. .

Abstract

Introduction: Many patients with chronic obstructive pulmonary disease (COPD) may derive inadequate benefit from dry powder inhalers (DPIs) because of suboptimal peak inspiratory flow (sPIF).

Objectives: To assess the clinical burden of COPD by characterizing the clinical characteristics of participants with sPIF against medium-low resistance DPIs versus those with optimal PIF (oPIF) from two phase 3 clinical trials.

Methods: Baseline data were collected from two randomized, controlled, phase 3 trials (NCT03095456; NCT02518139) in participants with moderate-to-severe COPD. oPIF (60 L/min) against the medium-low resistance DPIs was used as the threshold for defining the PIF subgroups (<60 L/min (sPIF) vs ≥60 L/min (oPIF)).

Results: Most participants included in this analysis were White (92%) and male (63%); the mean (range) age was 65 (43-87) years. Participants with sPIF had significantly greater dyspnea than those with oPIF as measured using the modified Medical Research Council scoring (mean (95% CI): 2.1 (2.0-2.2) vs 1.6 (1.4-1.7); P < 0.001) and baseline dyspnea index (mean (95% CI): 5.1 (4.9-5.4) vs 6.1 (5.8-6.3); P < 0.001). Based on COPD Assessment Test scores, participants with sPIF had a higher COPD symptom burden than those with oPIF (mean (95% CI): 21.5 (19.7-23.3) vs 19.5 (18.6-20.4); P = 0.05).

Conclusion: In these trials, participants with COPD who had sPIF against the medium-low resistance DPIs had more dyspnea and worse health status than those with oPIF. These results demonstrate that sPIF is associated with a higher clinical burden as measured by patient-reported outcomes.

PubMed Disclaimer

Conflict of interest statement

JAO has served on advisory boards for AstraZeneca, Boehringer Ingelheim, GSK, Mylan Inc., Reckitt Benckiser, Sunovion Pharmaceuticals, and Theravance Biopharma US, Inc. DAM has served on advisory boards for AstraZeneca, Boehringer Ingelheim, GSK, Mylan, Sunovion Pharmaceuticals, Theravance Biopharma US, Inc., and Teva and is on the speaker's bureau for AstraZeneca, Boehringer Ingelheim, and Teva Pharmaceuticals. GND is an employee of Theravance Biopharma US, Inc. DAL is a contract employee of Theravance Biopharma US, Inc. EJM is an employee of Theravance Biopharma US, Inc. GDC was an employee of Theravance Biopharma US, Inc., at the time these trials were conducted.

Figures

Figure 1
Figure 1
Mean (a) mMRC score and (b) BDI in participants with oPIF and sPIF against the medium-low resistance DPIs. BDI = baseline dyspnea index; CI = confidence interval; DPI = dry powder inhaler; mMRC = modified Medical Research Council; oPIF = optimal PIF; PIF = peak inspiratory flow; sPIF = suboptimal PIF.
Figure 2
Figure 2
Mean CAT scores in participants with oPIF and sPIF against the medium-low resistance DPIs. CAT = COPD assessment test; CI = confidence interval; DPI = dry powder inhaler; oPIF = optimal PIF; PIF = peak inspiratory flow; sPIF = suboptimal PIF.
Figure 3
Figure 3
Mean percent predicted (a) FEV1 and (b) FVC in participants with oPIF and sPIF against the medium-low resistance DPIs. CI = confidence interval; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; IPR = ipratropium; oPIF = optimal PIF; PIF = peak inspiratory flow; sPIF = suboptimal PIF.
See this image and copyright information in PMC

References

    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2024 report. https://goldcopd.org/2024-gold-report/
    1. Tashkin D. P. A review of nebulized drug delivery in COPD. International Journal of Chronic Obstructive Pulmonary Disease . 2016;11:2585–2596. doi: 10.2147/copd.s114034. - DOI - PMC - PubMed
    1. Rogliani P., Calzetta L., Coppola A., et al. Optimizing drug delivery in COPD: the role of inhaler devices. Respiratory Medicine . 2017;124:6–14. doi: 10.1016/j.rmed.2017.01.006. - DOI - PubMed
    1. Muralidharan P., Hayes D., Jr., Mansour H. M. Dry powder inhalers in COPD, lung inflammation and pulmonary infections. Expert Opinion on Drug Delivery . 2015;12(6):947–962. doi: 10.1517/17425247.2015.977783. - DOI - PubMed
    1. Duarte A. G., Tung L., Zhang W., Hsu E. S., Kuo Y. F., Sharma G. Spirometry measurement of peak inspiratory flow identifies suboptimal use of dry powder inhalers in ambulatory patients with COPD. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation . 2019;6(3):246–255. doi: 10.15326/jcopdf.6.3.2018.0163. - DOI - PMC - PubMed

Publication types

Associated data